期刊文献+

ELFP方案治疗晚期食管癌35例

"ELFP" Scheme;in the treatment of advanced esophageal cancer 35 cases
在线阅读 下载PDF
导出
摘要 目的 观察足叶乙甙(VP-16)联合氟尿嘧啶(5-FU)、亚叶酸钙(CF)、顺铂(DDP)组成的ELFP方案治疗晚期食管癌的近期疗效和毒副反应.方法 35例晚期食管癌患者,给予ELFP方案化疗.VP-16 60 mg/㎡,静脉滴注,第1天,第3天和第5天;CF 200 mg,静脉滴注第1天~第5天;5-FU 500 mg/㎡,静脉滴注d 1~5;DDP 20 mg/㎡,静脉滴注第1天~第5天,21 d为1个周期.结果 35例晚期食管癌患者均可评价疗效,总有效率60.0%,其中CR4例,10例复治组有效率50.0%,CR1例.毒副反应主要为剂量限制性毒性,表现为Ⅲ~IV度骨髓抑制(5.7%).结论 ELFP方案治疗晚期食管癌有效率高,毒副反应可耐受. Objective To observe the etoposide (VP-16) combined with fluorouracil (5 -FU),leucovorin (CF),cisplatin (DDP) regimen consisting of ELFP advanced esophageal cancer efficacy and toxicity reaction. Methods 35 patients with advanced esophageal cancer patients, chemotherapy given EI.FP. VP - 16 60 mg/㎡ ,intravenous infusion, d 1,3,5 ; CF 200 rag, intravenous infusion d 1 - 5 ;5 - FU 500 mg/㎡,intravenous infusion d 1 -5;DDP 20mg / m , intravenous infusion d1 -5, 21 days for a period. Results 35 patients with advanced esophageal cancer patients can be evaluated, the total effective rate 60.0%, which CR4 cases, 10 cases re - treated group was 50.0%, CRI patients. Adverse reactions were dose - limiting toxicity, manifested as Ⅲ~IV treatment of advanced esophageal cancer is high, toxicity can be tolerated.
作者 庄海莲 赵梅
机构地区 泰安市中医医院
出处 《中外医学研究》 2010年第29期17-18,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 晚期食管癌 足叶乙甙 亚叶酸钙 氟尿嘧啶 顺铂 化疗 Advanced esophageal cancer Etoposide Leucovorin myelosuppression (5.7%). Conclusion ELFP effective Fluorouracil Cisplatin Chemotherapy
  • 相关文献

参考文献5

  • 1Ilson DH.Oesophageal Cancer:new developments in systemic therapy.Cancer Treat Rev,2003,29(6):525-532.
  • 2Anderson SE,Minsky BD,Bains M,etal.combined modallty therapy in esophageal cancer:the Memorial experience.Semrn Sung Oncol,2003,21(4):228-232.
  • 3安继业,王立东.食管癌单独化疗和联合放疗、化疗的应用进展[J].实用肿瘤杂志,2003,18(6):493-495. 被引量:14
  • 4Murok,Hamaguchi T,Ohtsu A,etal.A phase II study of single.agent docetaxel in patients with metastatic esophageal cancer.Ann Onc,2004,15(6):955-959.
  • 5Kroep JR,Pinedo HM,Giaceone G,etal.Phase II study of cisplatin preceding jemcitabine in patients with advanced esophageal cancer.Ann Onc,2004,15(2):230-235.

二级参考文献17

  • 1[1]Albertsson M.Chemoradiotherapy of esophageal cancer [J].Acta Oncol,2002,41(2):118-123.
  • 2[2]Geh JI. The use of chemoradiotherapy in oesophageal cancer [J]. Eur J Cancer, 2002,38(2):300-313.
  • 3[3]Ajani JA, Ilson DH, Kelsen DP.The activity of paclitaxel in gastrointestinal tumors[J]. Semin Oncol.1995,22(5 Suppl 12):46-50.
  • 4[4]Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma [J]. Cancer, 2002,94(3):641-646.
  • 5[5]Boku N, Ohtsu A, Shimada C, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer [J]. J Clin Oncol, 1999,17(1):319-323.
  • 6[6]Ajani JA,Baker J,Pisters PW,et al.Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma[J]. Oncology(Huntingt),2001,15(3 Suppl 5):52-54.
  • 7[7]Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study [J]. J Clin Oncol, 2000,18(3):455-462.
  • 8[8]Minsky BO, Berkey B, Kelsen DK, et al. Preliminary results of intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: standard vs high dose radiation therapy [J]. Proc Am Soc Clin Oncol, 2000,19:239a.
  • 9[9]Al-Sarraf M,Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer. An intergroup study [J]. J Clin Oncol, 1997,15(2):866.
  • 10[10]Wilson KS, Wilson AG, Dewar GJ. Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998 [J]. Can J Gastroenterol, 2002,16(6):361-368.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部